Onivyde (Irinotecan Liposome)

Onivyde (irinotecan liposome) is a topoisomerase inhibitor used, together with medicines fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression post-gemcitabine-based therapy. 

Limitation of Use: This medicinal product is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.

Recommended Dosage: The recommended dosage of Onivyde injection is 70 mg/m2 administered (prior to leucovorin and fluorouracil) by intravenous (IV) infusion over 90 minutes every 14 days (2 weeks). The recommended initial dosage in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m2 administered by intravenous (IV) infusion over 90 minutes. The dosage can be increased to 70 mg/m2 as tolerated in subsequent cycles. 

• Irinotecan liposome treatment can be responsible for causing severe or critical neutropenia and fatal neutropenic sepsis. Monitor complete blood cell (CBC) counts on Days 1st and 8th of every cycle and more frequently in case clinically required. 
  
• Onivyde 43 mg/10 mL can be responsible for causing severe and life-threatening diarrhea. Avoid administering this medicine to patients with bowel obstruction. A patient may experience both early and late-onset diarrhea. Withhold therapy for Grade 2-4 diarrhea. Start loperamide for late onset diarrhea of any severity.
  
• Irinotecan HCl can be responsible for causing severe and fatal interstitial lung disease (ILD). Stop treatment in individuals with new or progressive dyspnea, fever, and cough, pending diagnostic evaluation. Discontinue this treatment in patients with a confirmed diagnosis of interstitial lung disease. 
  
• Treatment with Irinotecan HCl can be responsible for causing severe hypersensitivity reactions, including anaphylactic reactions. Permanently discontinue the use of this medication in all those individuals who experience a serious hypersensitivity reaction.
  
• On behalf of the findings with irinotecan HCl and the mechanism of action of Onivyde 43 mg/10 mL suggest this medicine can cause fetal harm if administered to a pregnant woman. Females of reproductive age should consider relevant contraception during treatment and for 30 days after the last dose.
  

What documents are required to import ONIVYDE to India?

ONIVYDE (irinotecan liposome injection) can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
• Patients identity proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

ONIVYDE (irinotecan liposome injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Onivyde in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can help facilitate the supply of ONIVYDE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Onivyde 43 mg/10 mL price in India. 

Indian Pharma Network is able to source the ONIVYDE (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Onivyde®?

Irinotecan Liposome is a Generic Name for the trade name drug Onivyde®.

What is the Manufacturer’s Name of Onivyde®?

Onivyde® is manufactured by Merrimack Pharmaceuticals, Inc.  

Is Onivyde® approved by the FDA?

Yes, Onivyde® is approved by the FDA. Date of approval: October 22, 2015.

Where can I get Onivyde® at the best price in India?

To get the best Onivyde price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Onivyde®, a medical prescription is needed from a treating physician.

What is the dosage and form of Onivyde® supplied?

Onivyde® is supplied as Injections: 43 mg/10 mL single-dose vial for intravenous (IV) administration. 

What are the most common side effects of Onivyde®? 

The most common side effects of Onivyde® are vomiting, diarrhea, fatigue/asthenia, nausea, decreased appetite, pyrexia, and stomatitis.

How much does Onivyde® cost in India?

The cost of Onivyde in India can vary. In order to procure this topoisomerase inhibitor legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Onivyde®?

Store the vials at 2°C to 8°C (36°F to 46°F). Never freeze it. Protect this medicinal product from light. 

Is it safe to buy Onivyde® online in India?

Yes, one can buy Onivyde online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Onivyde® through legal channels.